Next step towards malaria control
In infants, data has shown for the first time that the vaccine candidate can be administered as part of existing African national immunization programme. In children aged 5 to 17 months, the candidate RTS,S/AS01 reduced the risk of clinical episodes of malaria by 53% over an 8-month follow-up period and was shown to be safe.
The studies, conducted in Kenya and Tanzania, were this week presented at the American Society for Tropical Medicine and Hygiene annual meeting.
Although largely under control in South Africa, malaria has devastated many countries in sub-Saharan Africa specifically targeting children under five whose immune systems are not fully developed.
World Health Organisation (WHO) statistics reveal that about 1-million people die from malaria each year with 90 percent of these cases recorded in 35 sub-Saharan African countries.
Over 250-million cases of malaria are recorded every year and in some countries a quarter of those infected will die before they reach the age of five.
In any sub-Saharan African countries malaria accounted for half of all hospital admissions and hospital costs. The cost of malaria in Africa is around US$30-billion with the costs at economic level devastating due to people being off sick.
RTS,S/AS is the leading candidate vaccine in a global effort to develop a malaria vaccine and it is expected that the candidate will now go to phase III trials in 2009.
‘The vaccine works alongside standard infant vaccines of WHO’s Expanded Program of Immunisationn, has a favorable safety profile, and has consistently shown a significant efficacy level. We can begin to foresee the difference this scientific breakthrough could make in the lives of millions of African children who suffer and die from this disease year after year,’ said Joe Cohen, a co-inventor of the vaccine and vice-president at GlaxoSmithKline Biologicals.
Author
-
Health-e News is South Africa's dedicated health news service and home to OurHealth citizen journalism. Follow us on Twitter @HealtheNews
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
-
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
-
You must include all of the links from our story, including our newsletter sign up link.
-
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
-
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
-
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
-
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
-
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
Next step towards malaria control
by healthe, Health-e News
December 10, 2008